Rujiao Liu

765 total citations
39 papers, 580 citations indexed

About

Rujiao Liu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rujiao Liu has authored 39 papers receiving a total of 580 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Rujiao Liu's work include Colorectal Cancer Treatments and Studies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Rujiao Liu is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Rujiao Liu collaborates with scholars based in China and United States. Rujiao Liu's co-authors include Ruixuan Geng, Zhe Zhang, Xichun Hu, Jinjia Chang, Chenchen Wang, Jin Li, Zhiyu Chen, Wenhua Li, Xiaotian Han and Dongmei Ji and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Rujiao Liu

36 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rujiao Liu China 12 268 250 130 123 83 39 580
Anchit Khanna Australia 10 512 1.9× 298 1.2× 112 0.9× 92 0.7× 58 0.7× 16 691
In Ae Park South Korea 12 186 0.7× 319 1.3× 88 0.7× 241 2.0× 93 1.1× 18 605
Sharareh Siamakpour‐Reihani United States 11 246 0.9× 146 0.6× 82 0.6× 169 1.4× 42 0.5× 25 531
Gou Watanabe Japan 11 201 0.8× 306 1.2× 67 0.5× 123 1.0× 57 0.7× 25 596
Meredith A. Tennis United States 14 334 1.2× 203 0.8× 135 1.0× 178 1.4× 40 0.5× 29 645
Joo‐Shik Shin Australia 14 239 0.9× 386 1.5× 105 0.8× 103 0.8× 97 1.2× 41 668
Natasha Musrap Canada 12 295 1.1× 164 0.7× 155 1.2× 149 1.2× 45 0.5× 15 628
Joongho Shin United States 8 251 0.9× 324 1.3× 161 1.2× 98 0.8× 149 1.8× 17 567
Šime Spaventi Croatia 14 310 1.2× 207 0.8× 113 0.9× 131 1.1× 92 1.1× 23 590

Countries citing papers authored by Rujiao Liu

Since Specialization
Citations

This map shows the geographic impact of Rujiao Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rujiao Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rujiao Liu more than expected).

Fields of papers citing papers by Rujiao Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rujiao Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rujiao Liu. The network helps show where Rujiao Liu may publish in the future.

Co-authorship network of co-authors of Rujiao Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Rujiao Liu. A scholar is included among the top collaborators of Rujiao Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rujiao Liu. Rujiao Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tian, Xin, Rujiao Liu, Long Zhang, et al.. (2025). Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Human Monoclonal Antibody TQC2938 Targeting the IL-33/ST2 Axis in Healthy Chinese Adults. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3425–A3425. 1 indexed citations
2.
Tian, Xin, Rujiao Liu, Long Zhang, et al.. (2025). Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Human Monoclonal Antibody TQC2731 Targeting Thymic Stromal Lymphopoietin (TSLP) in Health Chinese Adults. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3424–A3424. 1 indexed citations
3.
Liu, Wenting, Rujiao Liu, Bo Yu, et al.. (2025). Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC. Advanced Science. 12(20). e2415196–e2415196. 9 indexed citations
4.
Yang, Xiaoyi, Rujiao Liu, Juan Jin, et al.. (2025). Cancer stem cells-derived exosomal TSPAN8 enhances non-stem cancer cells stemness and promotes malignant progression in PDAC. Oncogene. 44(27). 2328–2341. 1 indexed citations
5.
6.
Park, Wungki, Jian Zhang, Farshid Dayyani, et al.. (2024). Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3002–3002. 5 indexed citations
7.
8.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2024). 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.. Journal of Clinical Oncology. 42(16_suppl). 3013–3013. 6 indexed citations
9.
Tolcher, Anthony W., Xiaohua Wu, Jian Zhang, et al.. (2023). A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2531–2531. 5 indexed citations
10.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2023). Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours. npj Breast Cancer. 9(1). 28–28. 36 indexed citations
11.
Ji, Dongmei, Shiyu Jiang, Qunling Zhang, et al.. (2023). Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor. Clinical and Translational Science. 16(8). 1396–1407. 1 indexed citations
12.
Wang, Hui, Wenrui Zhang, Rujiao Liu, et al.. (2022). Lack of bombesin receptor–activated protein attenuates bleomycin-induced pulmonary fibrosis in mice. Life Science Alliance. 5(11). e202201368–e202201368. 5 indexed citations
13.
14.
Li, Ye, Rujiao Liu, Zhengqing Yan, et al.. (2022). Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy. Frontiers in Oncology. 12. 830816–830816. 8 indexed citations
15.
Liu, Rujiao, Xiaoying Zhao, Weijian Guo, et al.. (2019). Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab. Clinical & Translational Oncology. 22(6). 928–934. 12 indexed citations
16.
Zhang, Hangyu, Rujiao Liu, Lulu Liu, et al.. (2018). Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients. Translational Oncology. 12(3). 426–431. 37 indexed citations
17.
Qu, Xiangping, Hui Wang, & Rujiao Liu. (2017). Recent insights into biological functions of mammalian bombesin-like peptides and their receptors. Current Opinion in Endocrinology Diabetes and Obesity. 25(1). 36–41. 9 indexed citations
18.
Liu, Rujiao, Jun Cao, Xiang Gao, et al.. (2016). Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumor Biology. 37(10). 14083–14088. 49 indexed citations
19.
Zhang, Zhe, Jiping Wang, Dongmei Ji, et al.. (2014). Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer. Clinical Cancer Research. 20(17). 4559–4573. 59 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anchit Khanna Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by Sharareh Siamakpour‐Reihani Breakdown of academic impact, for papers by Gou Watanabe Breakdown of academic impact, for papers by Meredith A. Tennis Breakdown of academic impact, for papers by Joo‐Shik Shin Breakdown of academic impact, for papers by Natasha Musrap Breakdown of academic impact, for papers by Joongho Shin Breakdown of academic impact, for papers by Šime Spaventi
Rankless by CCL
2026